FCGR2A and cancer: Inconsistencies in the significance of these SNPs could be due to the influence of other patient factors, such as cancer type, treatment regime and disease stage, which make it difficult to ascertain whether there is truly an association between FcγR polymorphisms and response to anti-cancer mAb therapy.